CTOR

Dopo l'orario di chiusura: .99 0.02 +2.06%

Citius Oncology Inc (CTOR)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1196)

(347) 627-0058

420 LEXINGTON AVE,, NEW YORK

Prossima data di guadagno

Ultimi documenti SEC

CTOR's Discussions on Twitter

Confronta CTOR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CTOR	0.97	74.83M	0	0	0	0.00
ZTS	176.42	79.51B	9.15B	2.43B	2.31B	4.92
TAK	13.53	42.89B	30.27B	1.93B	3.45B	0.444
HLN	9.43	42.57B	14.26B	1.55B	0	0.3327
TEVA	16.49	18.51B	16.77B	-959.00M	1.37B	-2.00
VTRS	13.00	15.37B	15.24B	-646.50M	1.88B	1.53

Citius Oncology Inc Borsa (CTOR) Ultime notizie

Citius Oncology Inc Azioni (CTOR) Dati Finanziari

Non sono disponibili dati finanziari per Citius Oncology Inc (CTOR). Controlla altri titoli per ulteriori informazioni.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Confronta CTOR con altri titoli

Citius Oncology Inc Borsa (CTOR) Ultime notizie

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - Kilgore News Herald

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - BioSpace

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - BioSpace

CTOR stock touches 52-week low at $1.02 amid market challenges - Investing.com India

CTOR stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa

CTOR stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa

CTOR stock touches 52-week low at $1.29 amid market challenges - Investing.com

Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com

Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga

CTMX stock rated an Overweight by Piper Sandler - Knox Daily

CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex

Cytek BioSciences Inc (CTKB)’s stock performance: a year in review - US Post News

Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News

CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News

Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's

Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex

XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World

CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada

CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - Nasdaq

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow

A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News

Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex

CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com

Citius Oncology Inc. (CTOR) requires closer examination - US Post News

Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks

CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle

Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.00, Reflecting a -11.11 Downturn - The Dwinnex

Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia

Citius Oncology Inc. completes strategic acquisition - Investing.com

Citius Oncology Finalizes Merger and Modifies Stock Structure - TipRanks

Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ

Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.47, Reflecting a -22.81 Downturn - The Dwinnex

Citius merges oncology subsidiary with TenX Keane - Yahoo Finance

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Quantisnow

Citius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024 - Marketscreener.com

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - ForexTV.com

TenX Keane addresses trading halt, continues toward combination closing - TipRanks

New Ontak on track as Citius wins FDA’s nod for Lymphir in CTCL - BioWorld Online

US FDA approves Citius' therapy for rare blood cancer - Reuters.com

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - PR Newswire

Citius Oncology Inc Azioni (CTOR) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a CTOR